Abstract：
:Rheumatoid arthritis (RA) is a chronic, generally progressive autoimmune disease that causes functional disability, significant pain and joint destruction, and leads to premature mortality. It is estimated to affect between 0.5 and 1.0% of the adult population worldwide, increases in prevalence with age and affects more women than men. The magnitude of the severe long-term economic consequences of RA has been underestimated in the past. Most patients with the disease require continuous treatment to retard or stop progression and to control disease flares. Many also require surgery, such as total hip or knee replacement. In addition to these direct costs, work disability leads to reduced productivity and early retirement, and as a result, substantial indirect costs. The individual and his or her family must cope with the feeling of loss of contribution to society combined with redefined social roles, and the effects of pain, fatigue, low self-esteem, mental distress and depression. A number of countries in North America and Europe have reported a decline in the incidence of RA in recent years, although geographical differences remain that may be associated with genetic, environmental or cultural factors. Nevertheless, patients with RA have not shared the improvements in survival rates seen with other diseases over the last 40 years, and have a mean reduction in life expectancy of between 5 and 10 years. Disease severity, activity and disability are strongly linked to premature mortality in patients with RA. The high direct and indirect costs associated with RA, together with the substantial morbidity and mortality affecting millions of people worldwide, underline the potential benefits of improved treatments for this chronic disease to patients, their families and society.
journal_name
Pharmacoeconomicsjournal_title
PharmacoEconomicsauthors
Kvien TKdoi
10.2165/00019053-200422001-00002subject
Has Abstractpub_date
2004-01-01 00:00:00pages
1-12issue
2 Suppl 1eissn
1170-7690issn
1179-2027journal_volume
22pub_type
杂志文章,评审abstract：:The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of denosumab (Amgen Inc., UK) to submit evidence for the clinical and cost effectiveness of denosumab for the prevention of fragility fractures in post-menopausal women, as part of the Institute's single technology appraisal (STA...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/11589310-000000000-00000
更新日期：2011-11-01 00:00:00
abstract：:The efficacy of granisetron in preventing acute nausea and vomiting during the 24 hours following chemotherapy in patients with cancer is equivalent to that of other serotonin 5-HT3 receptor antagonists (ondansetron and tropisetron) and similar to or greater than that of conventional antiemetic regimens such as metocl...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-199609040-00009
更新日期：1996-04-01 00:00:00
abstract：OBJECTIVES:To obtain utility estimates suitable for use in economic models for chronic spontaneous (idiopathic) urticaria (CSU). METHODS:Patient-level data from three randomized clinical trials-ASTERIA I, ASTERIA II and GLACIAL-were analysed. Health states were derived from the Urticaria Activity Score over 7 days (UA...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-015-0375-7
更新日期：2016-05-01 00:00:00
abstract：:The regulation of pricing and trade for in-patent medicines within the European pharmaceutical sector presents a major challenge. In conditions of large sunk costs and consumers with differential willingness to pay--between different Member States--an efficient way of pricing in-patent medicines is through price discr...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-200018001-00008
更新日期：2000-01-01 00:00:00
abstract：OBJECTIVE:To assess the economic efficiency of meloxicam, a cyclo-oxygenase (COX)-2 selective inhibitor, versus diclofenac and piroxicam in the UK for the treatment of patients with osteoarthritis and the impact on the NHS budget of substituting nonselective NSAIDs with meloxicam. Methods and perspective: A decision an...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-200321060-00007
更新日期：2003-01-01 00:00:00
abstract：BACKGROUND:The process of "mapping" is increasingly being used to predict health utilities, for application within health economic evaluations, using data on other indicators or measures of health. Guidance for the reporting of mapping studies is currently lacking. OBJECTIVE:The overall objective of this research was ...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-015-0312-9
更新日期：2015-10-01 00:00:00
abstract：BACKGROUND:Before the new round of healthcare reform in China, primary healthcare providers could obtain a fixed 15 % or greater mark-up of profits by prescribing and selling medicines. There were concerns that this perverse incentive was a key cause of irrational medicine use. China's new Essential Medicines Program (...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-013-0068-z
更新日期：2014-03-01 00:00:00
abstract：:The annual cost of managing migraine totals billions of US dollars. This retrospective economic analysis of a clinical trial comparing subcutaneous dihydroergotamine mesylate (DHE) with subcutaneous sumatriptan in the treatment of acute migraine is appropriate because, although each product has been shown to be effica...
journal_title：PharmacoEconomics
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.2165/00019053-199610010-00006
更新日期：1996-07-01 00:00:00
abstract：:The progressive increase in the prevalence of obesity and aging in the population is resulting in increased healthcare and disability spending. The burden of obesity is particularly relevant in old age, due to accumulating co-morbidities and changes in body composition. Sarcopenic obesity, a mix of over- and under-nut...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-014-0237-8
更新日期：2015-07-01 00:00:00
abstract：BACKGROUND:Pharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines. Routine adoption of pharmacogenetic tests requires evidence of their cost effectiveness. OBJECTIVE:The present review aims to systematically review published ec...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-016-0397-9
更新日期：2016-08-01 00:00:00
abstract：BACKGROUND:There are few empirical studies on the valuation of health profiles that describe the short-term fluctuations of chronic diseases. OBJECTIVE:This study aimed to value chronic obstructive pulmonary disease (COPD) health profiles, which describe the health of these patients over the course of 1 year from a so...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-200927060-00003
更新日期：2009-01-01 00:00:00
abstract：:The manufacturer of olaratumab (Lartruvo®), Eli Lilly & Company Limited, submitted evidence for the clinical and cost effectiveness of this drug, in combination with doxorubicin, for untreated advanced soft tissue sarcoma (STS) not amenable to surgery or radiotherapy, as part of the National Institute for Health and C...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-017-0568-3
更新日期：2018-01-01 00:00:00
abstract：BACKGROUND:Dengue disease poses a great economic burden in Malaysia. METHODS:This study evaluated the cost effectiveness and impact of dengue vaccination in Malaysia from both provider and societal perspectives using a dynamic transmission mathematical model. The model incorporated sensitivity analyses, Malaysia-speci...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-017-0487-3
更新日期：2017-05-01 00:00:00
abstract：BACKGROUND:The response to therapeutics varies widely in patients with depression and anxiety, making selection of an optimal treatment choice challenging. IDgenetix®, a novel pharmacogenomic test, has been shown to improve outcomes by predicting the likelihood of response to different psychotherapeutic medications. O...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-017-0587-0
更新日期：2017-12-01 00:00:00
abstract：:Open-heart surgery (OHS) is performed to bypass occluded arteries, replace malfunctioning cardiac valves or correct congenital abnormalities. The average cost of OHS varies from $US25 057-$US79 795 (1997 values). The objective of this paper was to review economic studies of pharmacological strategies in open-heart sur...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-200321040-00003
更新日期：2003-01-01 00:00:00
abstract：BACKGROUND:Health-related quality of life (HRQoL) is a key outcome in cost-utility analyses, which are commonly used to inform healthcare decisions. Different instruments exist to evaluate HRQoL, however while some jurisdictions have a preferred system, no gold standard exists. Standard meta-analysis struggles with the...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-019-00843-z
更新日期：2020-01-01 00:00:00
abstract：AIM:To assess the relative cost effectiveness of escitalopram compared with venlafaxine XR in patients with major depressive disorder (MDD). METHODS:An economic evaluation was conducted alongside a double-blind, multinational, randomised clinical trial and examined the costs and quality of life of 251 patients taking ...
journal_title：PharmacoEconomics
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.2165/00019053-200523020-00007
更新日期：2005-01-01 00:00:00
abstract：:Due to a single error in the annual cost of sarilumab the following needs to be corrected in the article. ...
journal_title：PharmacoEconomics
pub_type： 已发布勘误
doi：10.1007/s40273-019-00857-7
更新日期：2020-01-01 00:00:00
abstract：BACKGROUND:Lung cancer is among the top causes of cancer-related deaths. Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors can increase progression-free survival compared with standard chemotherapy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). OBJECTIVE:The aim o...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-015-0305-8
更新日期：2015-11-01 00:00:00
abstract：BACKGROUND:In the past decade, the range of contraceptives available has increased dramatically. There are limited data on the factors that determine women's choices on contraceptive alternatives or what factors providers consider most important when recommending contraceptive products to women. OBJECTIVES:Our objecti...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/11598040-000000000-00000
更新日期：2012-12-01 00:00:00
abstract：:There are insufficient resources in the UK to fund all new technologies and new indications approved by the National Institute for Health and Clinical Excellence (NICE). Diverting funding from existing sources will have a detrimental effect on the provision of other priority services. The UK Office of Fair Trading (OF...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-200826020-00001
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:The symptoms of attention-deficit hyperactivity disorder (ADHD) are associated with impairment in multiple domains of health-related quality of life (HR-QOL). HR-QOL of children with ADHD has been assessed by relatively long multidimensional questionnaires. A review of the literature found no studies using t...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-200523080-00004
更新日期：2005-01-01 00:00:00
abstract：:The broad spectrum of antibacterial activity and favourable pharmacokinetic profile of ciprofloxacin permit oral treatment of many serious infections which have traditionally necessitated parenteral antibacterial therapy. This has been demonstrated in comparative studies, in which ciprofloxacin was as effective and w...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-199303050-00007
更新日期：1993-05-01 00:00:00
abstract：:The application of cost-effectiveness methodology is particularly important in widespread diseases such as hypertension. However, because prospective cost-effectiveness analyses comparing different antihypertensive drugs are not currently available, differences in the cost effectiveness of these drugs can only be esti...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-199508060-00006
更新日期：1995-12-01 00:00:00
abstract：:Advanced controlled release (CR) dosage forms are relative newcomers to pharmaceutical markets, and few studies relate their efficacy, safety or compliance benefits to economic value. This literature review was undertaken to assess the cost effectiveness of CR dosage forms using such measures as purchase costs, total ...
journal_title：PharmacoEconomics
pub_type： 杂志文章,meta分析
doi：10.2165/00019053-199405060-00005
更新日期：1994-06-01 00:00:00
abstract：:The recent multinational, randomised, prospective studies Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE), Percutaneous Coronary Intervention substudy of CURE (PCI-CURE) and Clopidogrel for the Reduction of Events During Observation (CREDO) have demonstrated the clinical efficacy and safety of clopid...
journal_title：PharmacoEconomics
pub_type： 杂志文章,meta分析,多中心研究
doi：10.2165/00019053-200422004-00006
更新日期：2004-01-01 00:00:00
abstract：BACKGROUND:In many healthcare systems, affordability concerns can lead to restrictions on the use of expensive efficacious therapies. However, there does not appear to be any consensus as to the terminology used to describe affordability, or the thresholds used to determine whether new drugs are affordable. OBJECTIVES...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-017-0514-4
更新日期：2017-08-01 00:00:00
abstract：BACKGROUND:Assessment of health state and health-related quality of life (HR-QOL) are limited by a child's age and cognitive ability. Parent-proxy reports are known to differ from children's reports. Simultaneous assessment using a parent-child dyad is an alternative approach. OBJECTIVE:Our objective was to assess the...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/11597890-000000000-00000
更新日期：2012-08-01 00:00:00
abstract：BACKGROUND:Healthcare resource use data were collected for 1 year as part of the CAESAR (Canada, Australia, Europe, South Africa) clinical trial, which evaluated the effect of adding lamivudine to treatment regimens containing zidovudine in patients with HIV infection. This study showed that lamivudine-containing regim...
journal_title：PharmacoEconomics
pub_type： 临床试验,杂志文章,多中心研究,随机对照试验
doi：10.2165/00019053-199915001-00003
更新日期：1999-01-01 00:00:00
abstract：:A variety of problems are associated with the operation, quality, costs, and benefits of therapeutic substitution programmes. Adequate communication of procedures, events, and failures are essential features of a safe therapeutic substitution policy. However, case reports of suboptimal therapy and differences in pha...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-199200011-00010
更新日期：1992-01-01 00:00:00
